Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.5570 -0.0247 (-4.25%)
Delayed Quote Updated: 11:31 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
From Invivyd, Inc.
Via GlobeNewswire
News headline image
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome
From Invivyd, Inc.
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd, Inc.
Via GlobeNewswire
News headline image
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval ↗
Invivyd (NASDAQ:IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined... 
Via MarketBeat
Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge ↗
Via Chartmill
News headline image
Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311
From Invivyd, Inc.
Via GlobeNewswire
News headline image
3 Small-Cap Biotechs With Binary Catalysts on the Calendar ↗
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices. 
Via MarketBeat
News headline image
Invivyd to Participate in Upcoming September Investor Conferences
From Invivyd, Inc.
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate in Upcoming Investor Events
From Invivyd
Via GlobeNewswire
News headline image
Invivyd (IVVD) Q1 2026 Earnings Transcript ↗
Invivyd (IVVD) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Invivyd Q1 Earnings Call Highlights ↗
Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to... 
Via MarketBeat
Topics Earnings
News headline image
Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
From Invivyd
Via GlobeNewswire
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
News headline image
Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.